|Publication Type||Journal Article|
|Year of Publication||2010|
|Authors||Hartland, CL, Youngsaye, W, Morgan, B, Ting, A, Nag, P, Buhrlage, S, Johnston, S, Bittker, J, Vincent, B, Whitesell, L, Dandapani, S, Macpherson, L, Munoz, B, Palmer, M, Lindquist, S, Schreiber, SL|
The effectiveness of the potent antifungal drug fluconazole has been compromised by the rise of drug-resistant fungal pathogens. It has been observed that inhibition of Hsp90 can reverse drug resistance in Candida; however, it is challenging to find fungal-specific inhibitors of Hsp90 that do not also impair the human host protein. The Molecular Libraries Probe Production Centers Network (MLPCN) library was screened in duplicate dosings to identify compounds that selectively reverse fluconazole resistance in a Candida albicans clinical isolate, while having no antifungal activity when administered as a single agent. An indazole compound (CID3243873) was identified as meeting most of the probe criteria, and subsequent SAR identified a more potent analog as a new probe compound (ML212).